Cargando…
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
BACKGROUND: Standardized salvage treatment has not yet proved effective in glioblastoma multiforme (GBM) patients who receive prior standard radiotherapy plus concomitant and adjuvant temozolomide. METHODS: Patients with progressive GBM after radiotherapy plus concomitant and/or adjuvant temozolomid...
Autores principales: | Brandes, Alba A., Tosoni, A., Franceschi, E., Blatt, V., Santoro, A., Faedi, M., Amistà, P., Gardiman, M., Labianca, R., Bianchini, C., Ermani, M., Reni, M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2717374/ https://www.ncbi.nlm.nih.gov/pubmed/19169684 http://dx.doi.org/10.1007/s00280-009-0926-8 |
Ejemplares similares
-
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
por: Brandes, A A, et al.
Publicado: (2006) -
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
por: Franceschi, E, et al.
Publicado: (2007) -
Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)).
por: Marsoni, S., et al.
Publicado: (1990) -
V Meeting Nazionale Gruppo Italiano di Paleopatologia
Publicado: (2019) -
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)